# Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

> **NCT03355365** · PHASE2 · COMPLETED · sponsor: **Tisch Multiple Sclerosis Research Center of New York** · enrollment: 54 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Intrathecal MSC-NP injection
- **OTHER:** Intrathecal saline injection

## Key facts

- **NCT ID:** NCT03355365
- **Lead sponsor:** Tisch Multiple Sclerosis Research Center of New York
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-21
- **Primary completion:** 2023-02-09
- **Final completion:** 2023-04-17
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03355365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03355365, "Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03355365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*